Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology

被引:57
作者
Kassouf, Wassim
Sanchez-Ortiz, Ricardo
Tamboli, Pheroze
Tannir, Nizar
Jonasch, Eric
Merchant, Madhur M.
Matin, Surena
Swanson, David A.
Wood, Christopher G.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Urol, Unit 1373, Houston, TX 77030 USA
[2] McGill Univ, Ctr Hlth, Div Urol, Montreal, PQ, Canada
[3] Univ Puerto Rico, Sch Med, Div Urol, San Juan, PR 00936 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[6] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
kidney; carcinoma; renal cell; nephrectomy; neoplasm metastasis; histology; comparative;
D O I
10.1016/j.juro.2007.07.037
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To our knowledge the benefit of cytoreductive surgery for patients with metastatic renal cell carcinoma with nonclear cell histology is unknown. In this retrospective study we report our experience with cytoreductive nephrectomy for nonclear cell metastatic renal cell carcinoma at M. D. Anderson Cancer Center. We compared the outcomes with those in patients with clear cell metastatic renal cell carcinoma. Materials and Methods: From 1991 to 2006, 606 patients with metastatic renal cell carcinoma underwent cytoreductive nephrectomy and they formed the basis of this report. Of these patients 92 had nonclear cell metastatic renal cell carcinoma. The remaining 514 patients had clear cell metastatic renal cell carcinoma and they formed a comparative group. Multivariate Cox regression analysis was performed to evaluate the relationship between clinical variables and histology (clear cell vs nonclear cell) on disease specific survival. Results: Compared with patients with clear cell histology those with nonclear cell metastatic renal cell carcinoma were younger (p = 0.0001), and more likely to have nodal metastases (p < 0.0001) and sarcomatoid features (23% vs 13%, p = 0.026). On multivariate analysis median disease specific survival in patients with nonclear cell histology was significantly worse than that in patients with clear cell metastatic renal cell carcinoma (9.7 vs 20.3 months, p = 0.0003) even after adjusting for T stage, grade, performance status, age and sarcomatoid features. Sarcomatoid features were a predictor of poor outcome in cases of clear and nonclear cell histology, although even in the absence of sarcomatoid features nonclear cell histology was associated with worse disease specific survival (p = 0.017). Interestingly although there was a significantly higher incidence of positive nodes in patients with nonclear histology (p < 0.0001), this phenotype was not associated with a worse disease specific survival, as it was in those with clear cell histology (p = 0.0001). In fact, patients with node negative disease with nonclear cell histology had the worst prognosis overall in the entire group. Conclusions: Patients with nonclear cell metastatic renal cell carcinoma were younger and had a higher incidence of nodal metastases, a higher incidence of sarcomatoid features and a worse prognosis than those with clear cell histology who underwent cytoreductive surgery.
引用
收藏
页码:1896 / 1900
页数:5
相关论文
共 20 条
[1]   Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma [J].
Beck, SDW ;
Patel, MI ;
Snyder, ME ;
Kattan, MW ;
Motzer, RJ ;
Reuter, VE ;
Russo, P .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (01) :71-77
[2]   Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma [J].
Fallick, ML ;
McDermott, DF ;
LaRock, D ;
Long, JP ;
Atkins, MB .
JOURNAL OF UROLOGY, 1997, 158 (05) :1691-1695
[3]   Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer [J].
Flanigan, RC ;
Salmon, SE ;
Blumenstein, BA ;
Bearman, SI ;
Roy, V ;
McGrath, PC ;
Caton, JR ;
Munshi, N ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1655-1659
[4]   Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis [J].
Flanigan, RC ;
Mickisch, G ;
Sylvester, R ;
Tangen, C ;
Van Poppel, H ;
Crawford, ED .
JOURNAL OF UROLOGY, 2004, 171 (03) :1071-1076
[5]   Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma [J].
Han, KR ;
Pantuck, AJ ;
Bui, MHT ;
Shvarts, O ;
Freitas, DG ;
Zisman, A ;
Leibovich, BC ;
Dorey, FJ ;
Gitlitz, BJ ;
Figlin, RA ;
Belldegrun, AS .
UROLOGY, 2003, 61 (02) :314-319
[6]   Cancer statistics, 2006 [J].
Jemal, A ;
Siegel, R ;
Ward, E ;
Murray, T ;
Xu, JQ ;
Smigal, C ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130
[7]   Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma [J].
Levy, DA ;
Swanson, DA ;
Slaton, JW ;
Ellerhorst, J ;
Dinney, CPN .
JOURNAL OF UROLOGY, 1998, 159 (04) :1168-1172
[8]   Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial [J].
Mickisch, GHJ ;
Garin, A ;
van Poppel, H ;
de Prijck, L ;
Sylvester, R .
LANCET, 2001, 358 (9286) :966-970
[9]   Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience [J].
Motzer, RJ ;
Bacik, J ;
Mazumdar, M .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6302S-6303S
[10]   Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology [J].
Motzer, RJ ;
Bacik, J ;
Mariani, T ;
Russo, P ;
Mazumdar, M ;
Reuter, V .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2376-2381